Just Saying!, page-2

Its just that by now revenues should have been nearer $60m a year whereas all this hand holding of leads and long testing times have meant the revenues and profits still haven't caught up with the market cap despite the share price coming down to meet it.
But that said, I can still imagine all this build up will eventually create a J-curve style of exponential growth that will justify the three years of missed opportunities elsewhere, certainly it is largely de-risked now. I missed the Sydney presentation, but from reports and observations from the writing, Looks like we have a good CEO in place with a background in the chemistry.
While NC's departure might have been read as detrimental by the market, it obviously hasn't done more than bring it back again to its perceived support where upside potential offsets downside risk.
In the end, the early broker reports that suggested it would all start happening in 2019 have proved correct. Just their target price of $1 in 2016 was premature two years ago.
Oh well, back to breadmaking, gardening and getting the boat ready for kingfishing tomorrow. No point watching it at present.